Nuclera and leadXpro Partner to Accelerate AI-Driven Drug Discovery for Challenging Membrane Proteins
核心洞察
Nuclera (搜索) and leadXpro (搜索) announced a scientific partnership combining eProtein Discovery (搜索)'s rapid multiplex membrane protein screening with leadXpro's AI/ML-driven construct design expertise.
The collaboration establishes an AI-guided, end-to-end workflow linking in silico construct design with experimental screening to accelerate structure-based drug discovery for challenging membrane protein targets.
Membrane proteins (搜索) remain among the most valuable yet difficult drug targets due to challenges in expression and purification for structural biology studies.
Nuclera (搜索), the biotechnology company enabling rapid access to high-quality proteins, and leadXpro (搜索), a specialist in structure-based drug discovery for membrane proteins (搜索), announced a scientific partnership to advance therapeutic development through AI-guided workflows. The collaboration integrates eProtein Discovery (搜索)'s rapid multiplex membrane protein screening technology with leadXpro's artificial intelligence and machine learning-driven construct design expertise.
Addressing Critical Drug Discovery Bottlenecks
Membrane proteins (搜索) represent some of the most valuable yet challenging drug targets in pharmaceutical development. These proteins are notoriously difficult to express and purify in sufficient quantity and quality for structural biology and biophysical studies, creating significant barriers for drug discovery programs even when the underlying biology is well understood.
The partnership addresses these challenges by establishing an AI-guided, iterative, end-to-end workflow that links in silico construct design with rapid experimental multiplex screening. This integrated approach aims to accelerate and de-risk challenging membrane protein programs while shortening the path to critical structural and biophysical insights required for structure-based drug discovery.
Integrated Technology Platform
Under the collaboration, membrane protein constructs will be screened using Nuclera (搜索)'s eProtein Discovery (搜索) System, with the most promising variants undergoing detailed biophysical characterization and high-resolution cryo-EM structure determination led by leadXpro (搜索). The insights generated from these studies will be integrated into AI/ML models for construct design and stability predictions, improving yields, functionality, and success rates.
The partnership will also inform future integration of AI/ML capabilities into Nuclera (搜索)'s product portfolio to embed predictive design into the eProtein Discovery (搜索) System, while strengthening leadXpro (搜索)'s platform capabilities for rapidly producing and characterizing difficult membrane protein targets.
Industry Leadership Perspectives
"Scientists are under pressure to progress increasingly complex membrane protein programs faster," said Dr. Michael Chen, CEO and Co-Founder of Nuclera (搜索). "By partnering with leadXpro (搜索), we can pair AI/ML-driven construct design with our rapid multiplex membrane protein screening to provide a truly 'lab-in-loop' workflow. This collaboration is an important step towards embedding AI/ML into Nuclera's system so that researchers can go from sequence to high-value structural and functional insights in a fraction of the time currently required."
Dr. Michael Hennig, CEO of leadXpro (搜索), emphasized the critical importance of optimized membrane protein constructs: "Access to well-optimized membrane protein constructs is critical for producing high-quality proteins that enable biophysical and structural biology studies. Nuclera (搜索)'s eProtein Discovery (搜索) platform provides a robust, rapid, and reproducible approach to exploring construct space. Combined with our established AI/ML and structural biology expertise, this integration allows us to support better design decisions earlier and accelerate the progression of promising drug candidates."
Technology Integration and Future Applications
The collaboration brings together eProtein Discovery (搜索)'s Cell-Free Protein Synthesis multiplex screening technology with leadXpro (搜索)'s AI/ML and biophysical and structural characterization expertise. This integration creates a comprehensive platform designed to overcome traditional limitations in membrane protein drug discovery programs.
The partnership represents a significant advancement in applying artificial intelligence and machine learning to accelerate drug discovery timelines, particularly for complex membrane protein targets that have historically presented substantial technical challenges for pharmaceutical researchers.